Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares Bought by Jane Street Group LLC

Jane Street Group LLC grew its position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 106.5% during the third quarter, Holdings Channel.com reports. The firm owned 69,872 shares of the company’s stock after acquiring an additional 36,028 shares during the period. Jane Street Group LLC’s holdings in Verrica Pharmaceuticals were worth $101,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in shares of Verrica Pharmaceuticals by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock valued at $428,000 after acquiring an additional 4,393 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Verrica Pharmaceuticals by 20.4% during the 2nd quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock worth $194,000 after buying an additional 4,514 shares during the last quarter. Quest Partners LLC acquired a new position in shares of Verrica Pharmaceuticals in the 2nd quarter valued at $50,000. Renaissance Technologies LLC acquired a new position in shares of Verrica Pharmaceuticals in the 2nd quarter valued at $332,000. Finally, Simplify Asset Management Inc. purchased a new position in shares of Verrica Pharmaceuticals in the 2nd quarter valued at $2,041,000. 42.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VRCA has been the topic of several research reports. TD Cowen dropped their price objective on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, October 21st. HC Wainwright cut Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 6th. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd. Needham & Company LLC reissued a “hold” rating on shares of Verrica Pharmaceuticals in a report on Friday, December 20th. Finally, Royal Bank of Canada cut shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $11.00 to $2.00 in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.50.

Verrica Pharmaceuticals Stock Up 3.3 %

VRCA opened at $0.66 on Wednesday. Verrica Pharmaceuticals Inc. has a 52 week low of $0.61 and a 52 week high of $11.41. The business has a 50 day moving average price of $0.85 and a two-hundred day moving average price of $2.70. The company has a quick ratio of 1.22, a current ratio of 1.34 and a debt-to-equity ratio of 29.58. The company has a market cap of $29.90 million, a PE ratio of -0.36 and a beta of 1.49.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.12). Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The company had revenue of ($1.78) million for the quarter, compared to analysts’ expectations of $7.53 million. As a group, research analysts anticipate that Verrica Pharmaceuticals Inc. will post -1.42 EPS for the current year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.